Format

Send to

Choose Destination
Arab J Urol. 2017 Apr 18;15(2):83-93. doi: 10.1016/j.aju.2017.03.005. eCollection 2017 Jun.

Medical expulsive therapy for ureteric stones: Analysing the evidence from systematic reviews and meta-analysis of powered double-blinded randomised controlled trials.

Author information

1
Glasgow Royal Infirmary, Glasgow, UK.
2
Bristol Urological Institutes, North Bristol NHS Trust, Bristol, UK.
3
New Cross Hospital, Wolverhampton, UK.
4
University Hospitals Southampton NHS Trust, Southampton, UK.
5
Queen Elizabeth University Hospitals, Glasgow, UK.
6
Islamic Universities of Gaza, College of Medicine, Gaza, Palestine.

Abstract

OBJECTIVE:

To conduct a systematic review and meta-analysis investigating the efficacy and safety of medical expulsive therapy (MET) in low risk of bias (RoB) randomised controlled trials (RCTs).

METHODS:

A Cochrane style systematic review was conducted on published literature from 1990 to 2016, to include low RoB and a power calculation. A pooled meta-analysis was conducted.

RESULTS:

The MET group included 1387 vs 1381 patients in the control group. The analysis reveals α-blockers increased stone expulsion rates (78% vs 74%) (P < 0.001), whilst calcium channel blockers (CCBs) had no effect compared to controls (79% vs 75%) (P = 0.38). In the subgroup analysis, α-blockers had a shorter time to stone expulsion vs the control group (P < 0.001). There were no significant differences in expulsion rates between the treatment groups and control group for stones <5 mm in size (P = 0.48), proximal or mid-ureteric stones (P = 0.63 and P = 0.22, respectively). However, α-blockers increased stone expulsion in stones >5 mm (P = 0.02), as well as distal ureteric stones (P < 0.001). The α-blocker group developed more side-effects (6.6% of patients; P < 0.001). The numbers needed to treat for α-blockers was one in 14, for stones >5 mm one in eight, and for distal stones one in 10.

CONCLUSION:

The primary findings show a small overall benefit for α-blockers as MET for ureteric stones but no benefit with CCBs. α-blockers show a greater benefit for large (>5 mm) ureteric stones and those located in the distal ureter, but no benefit for smaller or more proximal stones. α-blockers are associated with a greater risk of side-effects compared to placebo or CCBs.

KEYWORDS:

ARR, absolute risk reduction; CCB, calcium channel blocker; Calcium channel blockers; MD, mean difference; MET, medical expulsive therapy; MeSH, medical subject headings; Medical expulsive therapy (MET); NNT, numbers needed to treat; RCT, randomised controlled trial; RR, risk ratio; RoB, risk of bias; Ureteric stones; Urinary stones; α-Blockers

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center